Holen Sie sich die Stockscreener-App
17.89
3.80%
0.68
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals’ Earnings Call Highlights Strategic Progress - TipRanks
Arrowhead Pharmaceuticals Advances RNAi Therapeutics Pipeline - TipRanks
Arrowhead Pharma's Analyst Rating and Price Target Maintained at $60.00 - AInvest
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Arrowhead reports Q3 EPS ($1.26), consensus ($1.10) - TipRanks
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS - Research Tree
Is Arrowhead Pharmaceuticals Inc. trending in predictive chart modelsStock Market Watch with Smart Filters - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals: A High-Conviction Biotech Play with Multi-Billion-Dollar Potential - AInvest
Quoin (QNRX) Q2 Loss Beats Estimates - AOL.com
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $29 to $45 - 富途牛牛
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Arrowhead Pharma stock price target lowered to $21 at Leerink Partners - Investing.com Canada
Arrowhead Pharmaceuticals: Balancing Promising Launch Preparations with Pipeline Uncertainties - TipRanks
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts - Investing.com
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts By Investing.com - Investing.com Canada
Arrowhead (ARWR) Q3 Revenue Drops 41% - AOL.com
Arrowhead Pharmaceuticals: Navigating a Narrowing Loss and a Pivotal Regulatory Timeline for Plozasiran - AInvest
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue - MarketScreener
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals: Buy Rating Affirmed on Promising Pipeline and Late-Stage Developments - TipRanks
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript - Mitrade
ARROWHEAD PHARMACEUTICALS Earnings Results: $ARWR Reports Quarterly Earnings | ARWR Stock News - Quiver Quantitative
Arrowhead Pharmaceuticals Q3 Revenue Surpasses Expectations with $27.8mln, Sarepta Milestone Earnings $100mln. - AInvest
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results - Business Wire
Arrowhead Pharmaceuticals shares fall 2.15% intraday as Sarepta Therapeutics reports strong earnings and resumes deliveries. - AInvest
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Prepares for Q3 Earnings Report - GuruFocus
TR | OpenAI4o Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $16.5 - 富途牛牛
Arrowhead sells rights of Hypertriglyceridemia candidate to Sanofi in Greater China for $265 M - BioSpectrum Asia
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi - Yahoo Finance
Sanofi grabs Chinese rights to Arrowhead rare disease drug - pharmaphorum
Is Arrowhead Pharmaceuticals Inc. a growth stock or a value stockFree Daily Trading Room Entry - Jammu Links News
Is Arrowhead Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough investment performance - Jammu Links News
When is Arrowhead Pharmaceuticals Inc. stock expected to show significant growthBuild a diversified portfolio for sustainable growth - Jammu Links News
How volatile is Arrowhead Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough investment performance - Jammu Links News
Is it the right time to buy Arrowhead Pharmaceuticals Inc. stockPhenomenal returns - Jammu Links News
What are the latest earnings results for Arrowhead Pharmaceuticals Inc.Achieve consistent high returns with low risk - Jammu Links News
Why is Arrowhead Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on emerging investment opportunities - Jammu Links News
Should I hold or sell Arrowhead Pharmaceuticals Inc. stock in 2025Unlock powerful trading strategies for gains - Jammu Links News
What are Arrowhead Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What analysts say about Arrowhead Pharmaceuticals Inc. stockOutstanding yields - Jammu Links News
How does Arrowhead Pharmaceuticals Inc. compare to its industry peersMaster the art of timing market moves - Jammu Links News
What drives Arrowhead Pharmaceuticals Inc. stock priceUnlock powerful portfolio optimization tools - Jammu Links News
What are analysts’ price targets for Arrowhead Pharmaceuticals Inc. in the next 12 monthsFree Predictions - Jammu Links News
Arrowhead Pharmaceuticals Sells Rights to Sanofi for Plozasiran in Greater China - AInvest
What is the dividend policy of Arrowhead Pharmaceuticals Inc. stockPost Market Watchlist For Every Investor - Jammu Links News
Arrowhead Pharmaceuticals Inc. Price Holds Above Key Fib LevelShort Term High Yield Stock Tips for Active Traders - metal.it
Arrowhead unit sells rights for plozasiran to Sanofi in Greater China - Seeking Alpha
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemi - GuruFocus
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Business Wire
0.04%
2.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):